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THERE have heen on I\' limited investIgations on the influence of HLA match on organ transplant outcome 
in African-AmericansKlK~ To ohtain this information, a 
multivariate analysis was performed of 31.291 cases of 
primarv cadaver kidney transplantation reported to the 
UNOS Scientific Registry between 1991 and 1995 .. ' The 
collection included 8111 African-Americans. for whom 
follow-up was to January I. 1997. The study involved a 
triple university collaboration involving experts in clinical 
transplantation. histocompatibilirv. and biostatistical meth-
odology. 
HLA MATCHING 
The Pittsburgh experience was excluded from the UNOS 
analysis and reported separatc1y.l hecause tacrolimus was 
routinely given during the period of case accrual. Neverthe-
less, 3.2% of the UNOS patients at other centers were 
treated with tacrolimus: 2.5% of the 8111 African-Ameri-
cans and 3.4% of the 23.180 .. all others." 
In the total collection of 31.291 cases. I-year graft 
survival with a zero mismatch was 89%. This fell by 3% to 
86% with a single mismatch at either the A. B, or DR locus. 
Within the full range of one to six mismatches. 4% more 
were lost. As reported in detail elsewhere,3 the small graft 
survival differences were statistically significant. 
But how significant were these survival differences clini-
cally? Part of the answer came from the distribution profile 
(Tahle 1). Only 174 (or 2.1 %) of the 8111 African-Ameri-
cans received a zero-mismatched kidnev. compared to 9.90/r 
in the 23.180 "all-other" population. At the other end of the 
matching scale. an additional 55R African-Americans (or 
0.9%) received a six antigen (full-house) mismatch. Thus. 
Table 1. Distribution of HLA Mismatches 
HL4. 
African-Americans mismatches All Others 
174 (2.1%) 0 2286 (9.9%) 
206 (2.5%) 1 1128 (4.9%) 
783 (9.7%) 2 3225 (13.9%) 
2037 (25.1%) 3 6034 (26.0%) 
2665 (32.9%) 4 5877 (25.3%) 
1688 (20.8%) 5 3509 (15.1%) 
Subtotal 9 1.2% Subtotal 85.3% 
558 (6.9%\ 6 1211(48%) 
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91.2";' of the African-American recipients werc in the one 
to five mismatch spectrum. which also bracketed more than 
85<;,( of the "all other" cases (Table I). 
The graft survival in African-Americans at the I-year 
posttransplant milestone was not markedly lower than that 
of the "all other" population at any of the HLA mismatch 
levels. More relevant to the primary objective of our study. 
the degree of HLA mismatch had very linle effect on I-year 
African-American outcome. One-year allograft survival 
from the top to bottom of the one to live HLA mismatch 
range varied by less than 2'7r (Table 2). The lack of a 
stepwise effect also was evident in the one to five mismatch 
range of the "all other" population. where the I-year 
survival did not vary by as much as 3% (Table 2). 
By 3 years. graft survival in African-Americans had 
become inferior to the "all others" (Table 2). However, 
because survival declined by approximately 10% at every 
level of HLA compatibility. including zero mismatches. the 
difference in 3-year graft survival from one to five mis-
matches was only 2.4%. with a survival crossover of four 
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Table 2. % Graft Survival at 1 and 3 Years 
African-Americans 
N = 8111 
87.1 (73.4) 
84.6 (68.7) 
84.3 (68.2) 
83.9 (67.5) 
83.0 (65.9) 
83.3 (663\ 
Subtotal 91.2% 
81.5 (63.2\ 
HL4. All Others 
mismatches N = 23180 
0 
1 
2 
3 
4 
5 
6 
89.2 (82.3) 
86.9 (78.7) 
86.4 (77.9) 
86.2 (77.6) 
84.5 (75.0) 
84.0 (74.3) 
Subtotal 85.3% 
83.0 (72.9) 
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Fig 1. Graft survival and calcu-
lations of hazard ratios (relative 
risk) over the first 3 post-trans-
plant years. based on number of 
HLA mismatches. The reference 
was provided by zero mismatch 
cases. HL = half life. 
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and five HLA mismatched tiers. The pattern of results in 
the "all other" recipient population (Table 2) was essen-
tially the same. 
although there was a small effect from the fifth to the sixth 
mismatch. At all levels of HLA mismatch. however, the 
principal and relative separation of curves had already 
occurred by the end of the first year (Table 2). Although the 
percentages were slightly different in the 23.180 "all other" 
cases, the overall picture was much the same. 
An HLA-associated survival divergence between 1 and 3 
years within the African-American population was obvious 
only with the stepdown from zero to the first mismatch, 
African-American (n=8, 111) 
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Fig 2. Relative risks of graft fail- I 
ure in African-Americans based 
on cumulative HLA mismatches. 
uSing one HLA mismatch popu-
lation for the reference (hazard 
ratio = 1.0). The HR for cyclo-
SDOrine was calculated with ta-
crolimus as reference. The HR 
for African-American status was 
calculated uSing "all others" as 
reference (1.0). 
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Fig 3. Relative risks of graft failure in "al\ other" than African-
American recipients based on cumulative HLA mismatches 
using one HLA mismatch population as the reference (1,0), The 
reference hazard ratio for cyclosporine was provided by tacroli-
mus, 
In Figure I. the hazard ratio (or relative risk) over the 
first 3 years with various degrees of mismatch in African-
Americans (left) or in all others (right). was calculated 
using the zero HLA mismatch as the reference standard of 
1.0, The principal adverse effect came with the first mis-
match. which for the African-Americans increased the 
relative risk of graft loss within 3 years to a modest 1.2. 
However. the relative risk only increased further to 1.3 from 
one to five mismatches. For the "all other"" population (Fig 
1. right), the relative risk between one and five mismatches 
rose from 1.2 to 1.5. 
It has been known for more than 25 vears that the 
absence of an HLA incompatibility (zero ~ismatch or six 
antigen mismatch) confers a graft survival advantage:'" The 
practical question is what is the effect of various levels of 
mismatch, Consequently. the relative risk of cumulative 
mismatches was recalculated using the one HLA mismatch 
as the reference standard of 1,0, The relative risk for both 
African-American and the "'all other"" patients with a zero 
mismatch was then 0,83 (Figs 2 and 3). The relative risk in 
the spectrum of one to five mismatches that encompassed 
9 I. 2 (;{, of all African-American recipients increased onl\ 
from 1.0 to 1.08 (Fig 2), This was less than the condition pe'r 
se of being African-American versus "all other"" (relative 
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Table 3, CREG Matched Cases (31.291) 
CREG 
Match/Mismatch 
2460/2460 
471/1334 
416/4008 
206/8071 
57/8542 
0/5197 
0/1679 
100% 
35,3% 
10.4% 
2.6% 
0.7% 
00/0 
0% 
For one to tlve HLA mlsmatcnes. CREG mJ1Cn vleld if.' 1150) 'v\,'as 3.6("'. 
3735 
n:-,f, fK-D~ tlsln~ "":111 others" d.S the rderence uf 1.01. and it 
\\<lS \cs'> thall the risk oj trcatlll!! \Iith nl"iosporillc (1.311 
rather than with tacroitmus (1.(1) (Fig 2), 
In the ""all other" population Eci~:;FK the rciativc risk fl)Sl' 
unl\' lrom the relen:nce of 1.(1 provided hv the Slll!.!1e HL\ 
lllism;ltch to 1.2; with live mismatches. :·\s with ',-\iric;llI-
:\mericans. thiS increasc in risk oj graft loss over a 3-year 
period was less than what incurred with choice of cyclospo-
rine-hased immunoslIppression (I.-L') verSlIS tacrolimus 
( I.()), 
CREG MATCHING 
Because it has been suggested that matching of cross 
reactive antigen groups (the so-called CREGs or public 
determinants) can be more discriminatinl!,',,7 we examined 
the eflcct of the CREG match in the 31.2y I UNOS cases, 
The computer program of Takemoto et ai" was used to 
convert the conventional HL\ phenotypes to CREGs, 
We began with a distrihution study (Table 3). Because 
CREG matching is directlv derived from HLA phenotypes. 
the 2460 zero HLA mismatched UNOS cases were by 
definition also CREG matched (a IOWI{ yield), eoweve~K 
with the succession from one to four HLA mismatches. the 
CREG match yield fell to 35'/C. 10<:;'.2,50. and less than 
I % in the respective tiers. There were no CREG matches in 
the five and six HLA mismatched categories (Table 3), 
The overall yield of CREG matches from the one to five 
HLA population in which 90<;( of the UNOS recipients fell 
was only 3.6':0. qhe~e CREG-matched organs had gone to 
only 3,2% of the 7937 African-Americans ~ho did n~t get a 
zero HLA mismatched kidnev (Table 4), The vield rate was 
onlv 4.3% of the comparable' 20.894 "all othe~s" (Table 4 l, 
The next question was whether the CREG-matched 
kidneys were associated with an improved graft survival in 
the miniscule fraction of the patients in which thev were 
used. This analysis is heing reported in detail cise~herCK"D 
Interpretation of the results in the African-American recip-
ients was undermined hv inexplicable findings. The 81 
CREG-matched patients from the one HLA mismatch tier 
(Table 4) had a nearl\' 10':( higher graft survival at 3 years 
than the 174 zero HLA misma;ched-patients (Table I; who 
hy definition also were CREG matched. Survival should 
have been essentiallv the same, In addition. CREG mis-
matched patients from the pooled two to four HLA incom-
Table 4. CREG-Matched Cases in Different HLA 
Mismatch Tiers 
HLA 
Afncan-Amenc3n mIsmatches All Others 
174/174 (100go) 0 2286/2286 (100%) 
81/206 (39.3%) 1 390/1128 (34,6%) 
172/5485 (3.1 % I 2-4 507/15136 (3,3%) 
0/2246 (0%) 5,6 0/6034 (0%1 
CREG Matcn Yield Other Than 0 HLA Match 
253/7937 (3.2%1 897/20894 (43%) 
" 
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patlbility tIers actually did better than patlellts who were 
CREG matched.' 
In the "all other"' population. no distinctioll could be 
made between the CREG matched and mismatched pa-
tients in any of the one to four HLA defined tiers. all of 
which had graft survival below the zero HLA mismatch 
standard. as expected.' 
DISCUSSION AND CONCLUSIONS 
Three conclusions are justified about the use of HLA 
matching as an instrument of organ distribution. First. short 
of a zero mismatch. allocation of primary cadaver kidneys 
by graded HLA incompatibility scoring has little effect on 
overall short- or long-term graft survival. Second, the 
current allocation policies prejudice the candidacy of Afri-
can-Americans and other hard-to-match populations. 
Third, tacrolimus-based immune suppression influenced 
outcome more than the cumulative effect of all HLA 
mismatches beyond the first one. 
There was no clear evidence that CREG matched pri-
mary cadaver kidney allografts survived better than CREG 
mismatched kidneys (reported elsewhere'). Furthermore. 
SCANTLEBURY GJERTSON. ELlASZIW ET AL 
the distribution studv descrihed showcd that CREG match· 
ing. even if predictIve of outcome. would not correct organ 
allocation inequities. Theretore. prospective matching trials 
either arc not justified or must be viewed as Helsinki 
Declaration Type I (acquisition of human knowledge) 
experiments. Such experiments must not be done without 
informed consent. specificd analyses. and conditions of trial 
stoppage. 
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